EICHOR
● Active Not Recruiting
Study of Pembrolizumab Given Prior to Surgery and in Combination With Radiotherapy Given Post-surgery for Advanced Head and Neck Squamous Cell Carcinoma (MK-3475-689)
Condition: Head and Neck Neoplasms · Sponsor: Merck Sharp & Dohme LLC
About this study
This is a randomized, active-controlled, open-label study of pembrolizumab given prior to surgery and pembrolizumab in combination with standard of care radiotherapy (with or without cisplatin), as post-surgical therapy in treatment naïve participants with newly diagnosed Stage III/IVA, resectable, locoregionally advanced, head and neck squamous cell carcinoma (LA-HNSCC). Efficacy outcomes will be stratified by programmed cell death ligand 1 (PD-L1) combined positive score (CPS) status. The primary hypothesis is that pembrolizumab given before surgery and after surgery in combination with radiotherapy (with or without cisplatin) improves event-free survival compared to radiotherapy (with or without cisplatin) given after surgery alone.
This description comes directly from the study's public registry record.
Talk to the study team
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
Locations (192)
| Moores Cancer Center ( Site 1885) | La Jolla, California, United States | — |
| University of Southern California Norris Comprehensive Cancer Center ( Site 1850) | Los Angeles, California, United States | — |
| Hoag Memoriall Hospital Presbyterian ( Site 2056) | Newport Beach, California, United States | — |
| UC Davis Health System ( Site 1864) | Sacramento, California, United States | — |
| St. Joseph Heritage Healthcare ( Site 1806) | Santa Rosa, California, United States | — |
| University of Colorado Cancer Center ( Site 1838) | Aurora, Colorado, United States | — |
| MedStar Washington Hospital Center ( Site 2062) | Washington D.C., District of Columbia, United States | — |
| George Washington University Medical Faculty Associates ( Site 2035) | Washington D.C., District of Columbia, United States | — |
| University of Florida ( Site 1832) | Gainesville, Florida, United States | — |
| University of Miami, Sylvester Comprehensive Cancer Center ( Site 2008) | Miami, Florida, United States | — |
| AdventHealth Orlando-AdventHealth Medical Group Hematology & Oncology at Orlandoc ( Site 2054) | Orlando, Florida, United States | — |
| Orlando Health Cancer Institute ( Site 2061) | Orlando, Florida, United States | — |
+ 180 more locations — full list on the registry record.
Follow this study
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT03765918